

ASX Announcement

Medibio Limited – 10 April 2017



Medibio enters fully funded Paediatric mental illness diagnostic research Joint Venture

- Medibio/PHI diagnostic research to focus on range of child mental disorders
- Paediatric Depression, Anxiety Disorder, ADHD and PTSD
- 17 million children in US suffer a psychiatric disorder
- PHI established to collaborate research for global solutions for paediatric health
- Partnership aims to develop clinical diagnostic products for 0 to 18 age group

Sydney, Australia – 10 April 2017: Medibio Limited (MEB or the Company) is pleased to report that it has entered a binding Joint Venture agreement with Dr Paul Porter, Lead Investigator; PHI (Partnerships for Health Intelligence) Project. The purpose of the joint venture is to develop clinical diagnostic products for the 0 to 18 (paediatric) age group.

The joint venture will focus on the development of a clinical decision support tool for paediatric Depression, Anxiety Disorder, Autism, Attention Deficit Hyperactivity Disorder (ADHD), Schizophrenia and Post-Traumatic Stress Disorder.

It has been estimated that of the 74.5 million children in the United States, 17 million have or have had a psychiatric disorder - more than the number of children with cancer and diabetes combined¹.

Under the agreement, PHI will conduct and fund 100% of the clinical trials up until the completion of proof of concept, defined as the pre-submission meeting for the purposes of submitting the Product to the FDA or CE for approval. PHI will manage all day to day activities of the joint venture including data collection and clinical trials. Medibio will undertake all necessary algorithmic, statistical and analytical work and take responsibility for the registration of worldwide patents.

Utilising a global collaborative research model, the PHI Project is a strategic initiative to integrate technology and child health research to create innovative solutions for existing child health problems. The PHI team has successfully undertaken collaborative research projects to develop innovative technologies for various biotechnology companies. PHI has expertise in integrating research studies into hospitals and clinical activities ensuring swift uptake into clinical practice and hospital guidelines.

This joint venture is a 50:50 agreement with Medibio having the right to move from 50% to 75% of the joint venture in relation to paediatric depression, anxiety disorder and schizophrenia at the completion of proof of concept. To do this Medibio must refund PHI 100% of its expenditure and a further 200% of expenditure upon receipt of first revenue.

For personal use only

“The PHI team are embracing the opportunity to develop objective, accurate diagnostic tools for Paediatric Mental Health Disorders” Dr Porter commented. “We have long identified the need for a better diagnostic system along with an accurate measure of improvement with treatment. We believe that the Medibio technology will revolutionize existing mental health diagnostic methods which is reliant upon subjective assessment; and in so doing, will potentially improve outcomes for children, families and communities.”

In commenting on the agreement Mr Jack Cosentino the Managing Director of Medibio said “This joint venture with PHI represents another excellent and high value opportunity for Medibio to build on its growing industry position as a clinical decision support system looking at autonomic nervous system dysfunction. By working together with clinical leaders in various aspects of mental health research and treatment, not only are these partnerships assisting us in validating our unique technology for mental health diagnosis but we also expand our reach and awareness as we find new avenues for our unique diagnostic solution to bring real and effective solutions.

With a clear and recognised need for an object solution for all types of mental illness Medibio continues to engage in similar preliminary discussions with a number of organisations that will advance the company’s development and we look forward to informing the market as these progress.”

About PHI

The PHI (Partnerships for Health Intelligence) Project, headquartered at Joondalup Health Campus, Western Australia is a strategic initiative to integrate technology and child health research to create innovative solutions for global child health problems. The PHI Project is directed by Dr Paul Porter, Adjunct Associate Professor, Faculty of Health Science, Curtin University.

PHI utilizes a collaborative research model led by experienced senior clinicians and experts in engineering, artificial intelligence and algorithm development. The PHI network includes collaborations with investigators from universities and hospitals throughout Australia, South Africa, Finland, UK and the USA; as well as local community and advocacy groups.

PHI has established the infrastructure and networks necessary for undertaking research with global partners. The team is experienced in developing and progressing ideas from concept through to clinical practice. PHI provides guidance for university and hospital based projects to be undertaken with external organisations in an enterprise-driven approach which expedites research and generates new ideas for the use and application of knowledge. PHI has experience in embedding research within hospitals to better guide clinical practice, foster best practice review and inform health policy.

The PHI Project acquires, retains and develops expertise to create innovative technology solutions to existing child health problems. The PHI Project supports the development of innovative ideas generated by all researchers.

For personal use only

| | | |
|--|---|---|
| Further Information: | | Website: www.medibio.com.au |
| Medibio Shareholder Enquiries to: Jack Cosentino CEO and Managing Director Medibio Limited jack.cosentino@medibio.com.au T: + 1 612 314 7201 | Medibio Media Enquiries to: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0)412 036 231 | |

About Medibio Limited

Medibio (ASX: MEB), is an evidence-based medical technology company that will radically change how mental health care is delivered through objective, data driven assessment & management. Mental health represents the largest clinical problem today with an estimated 350M people world-wide suffering from depression. Given the subjective nature of the clinical assessments, less than 10% of patients receive optimal therapy on initial assessment. To address the clinical need, Medibio has developed an analytic platform that utilizes a patented (and patent pending) panel of circadian, sleep and autonomic system biomarkers to objectively quantify and characterize mental illness. Medibio has a rich portfolio of products to address broad spectrum mental health with strong foundation IP. Medibio's first product, a depression diagnostic aid, is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Located in Melbourne (Vic) Medibio is listed on the Australian Securities Exchange Ltd.

1. http://www.speakupforkids.org/ChildrensMentalHealthReport_052015.pdf